Summary

Sexually Transmitted Diseases (STD) Diagnostics Market – Scope of Report
TMR’s report on the global sexually transmitted diseases (STD) diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global sexually transmitted diseases (STD) diagnostics market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global sexually transmitted diseases (STD) diagnostics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the sexually transmitted diseases (STD) diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global sexually transmitted diseases (STD) diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global sexually transmitted diseases (STD) diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global sexually transmitted diseases (STD) diagnostics market.

The report delves into the competitive landscape of the global sexually transmitted diseases (STD) diagnostics market. Key players operating in the global sexually transmitted diseases (STD) diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global sexually transmitted diseases (STD) diagnostics market profiled in this report.

Key Questions Answered in Global sexually transmitted diseases (STD) diagnostics Market Report
• What is the sales/revenue generated by sexually transmitted diseases (STD) diagnostics across all regions during the forecast period?
• What are the opportunities in the global sexually transmitted diseases (STD) diagnostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Sexually Transmitted Diseases (STD) Diagnostics Market – Research Objectives and Research Approach
The comprehensive report on the global sexually transmitted diseases (STD) diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global sexually transmitted diseases (STD) diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global sexually transmitted diseases (STD) diagnostics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Sexually Transmitted Diseases (STD) Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecasts, 2020-2034
5. Key Insights
5.1. Key Product & Brand Analysis
5.2. Porter’s Five Forces Analysis
5.3. CDC’s 2022 Sexually Transmitted Disease (STI) Surveillance
5.4. Insights on Sexually Transmitted Infections in Low and Middle Income Countries
6. Global Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecasts, By Type of Diagnostic Test
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Type of Diagnostic Test, 2020-2034
6.3.1. Molecular Test
6.3.2. Serologic Test
6.3.3. Point of Care Test
6.3.4. Others (Immunological Test etc.)
6.4. Market Attractiveness By Type of Diagnostic Test
7. Global Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecasts, By Disease Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Disease Type, 2020-2034
7.3.1. Chlamydia
7.3.2. Gonorrhea
7.3.3. Syphilis
7.3.4. HIV/AIDS
7.3.5. Human Papillomavirus (HPV)
7.3.6. Genital Herpes
7.3.7. Others STDs
7.4. Market Attractiveness By Disease Type
8. Global Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecasts, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By End-user, 2020-2034
8.3.1. Hospitals & Clinics
8.3.2. Diagnostic Laboratories
8.3.3. Others (Research Institutes, Homecare Settings etc.)
8.4. Market Attractiveness By End-user
9. Global Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Type of Diagnostic Test, 2020-2034
10.2.1. Molecular Test
10.2.2. Serologic Test
10.2.3. Point of Care Test
10.2.4. Others (Immunological Test etc.)
10.3. Market Value Forecast By Disease Type, 2020-2034
10.3.1. Chlamydia
10.3.2. Gonorrhea
10.3.3. Syphilis
10.3.4. HIV/AIDS
10.3.5. Human Papillomavirus (HPV)
10.3.6. Genital Herpes
10.3.7. Others STDs
10.4. Market Value Forecast By End-user, 2020-2034
10.4.1. Hospitals & Clinics
10.4.2. Diagnostic Laboratories
10.4.3. Others (Research Institutes, Homecare Settings etc.)
10.5. Market Value Forecast By Country, 2020-2034
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type of Diagnostic Test
10.6.2. By Disease Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Type of Diagnostic Test, 2020-2034
11.2.1. Molecular Test
11.2.2. Serologic Test
11.2.3. Point of Care Test
11.2.4. Others (Immunological Test etc.)
11.3. Market Value Forecast By Disease Type, 2020-2034
11.3.1. Chlamydia
11.3.2. Gonorrhea
11.3.3. Syphilis
11.3.4. HIV/AIDS
11.3.5. Human Papillomavirus (HPV)
11.3.6. Genital Herpes
11.3.7. Others STDs
11.4. Market Value Forecast By End-user, 2020-2034
11.4.1. Hospitals & Clinics
11.4.2. Diagnostic Laboratories
11.4.3. Others (Research Institutes, Homecare Settings etc.)
11.5. Market Value Forecast By Country, 2020-2034
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type of Diagnostic Test
11.6.2. By Disease Type
11.6.3. By End-user
11.6.4. By Country
12. Asia Pacific Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Type of Diagnostic Test, 2020-2034
12.2.1. Molecular Test
12.2.2. Serologic Test
12.2.3. Point of Care Test
12.2.4. Others (Immunological Test etc.)
12.3. Market Value Forecast By Disease Type, 2020-2034
12.3.1. Chlamydia
12.3.2. Gonorrhea
12.3.3. Syphilis
12.3.4. HIV/AIDS
12.3.5. Human Papillomavirus (HPV)
12.3.6. Genital Herpes
12.3.7. Others STDs
12.4. Market Value Forecast By End-user, 2020-2034
12.4.1. Hospitals & Clinics
12.4.2. Diagnostic Laboratories
12.4.3. Others (Research Institutes, Homecare Settings etc.)
12.5. Market Value Forecast By Country, 2020-2034
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type of Diagnostic Test
12.6.2. By Disease Type
12.6.3. By End-user
12.6.4. By Country
13. Latin America Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Type of Diagnostic Test, 2020-2034
13.2.1. Molecular Test
13.2.2. Serologic Test
13.2.3. Point of Care Test
13.2.4. Others (Immunological Test etc.)
13.3. Market Value Forecast By Disease Type, 2020-2034
13.3.1. Chlamydia
13.3.2. Gonorrhea
13.3.3. Syphilis
13.3.4. HIV/AIDS
13.3.5. Human Papillomavirus (HPV)
13.3.6. Genital Herpes
13.3.7. Others STDs
13.4. Market Value Forecast By End-user, 2020-2034
13.4.1. Hospitals & Clinics
13.4.2. Diagnostic Laboratories
13.4.3. Others (Research Institutes, Homecare Settings etc.)
13.5. Market Value Forecast By Country, 2020-2034
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type of Diagnostic Test
13.6.2. By Disease Type
13.6.3. By End-user
13.6.4. By Country
14. Middle East & Africa Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Type of Diagnostic Test, 2020-2034
14.2.1. Molecular Test
14.2.2. Serologic Test
14.2.3. Point of Care Test
14.2.4. Others (Immunological Test etc.)
14.3. Market Value Forecast By Disease Type, 2020-2034
14.3.1. Chlamydia
14.3.2. Gonorrhea
14.3.3. Syphilis
14.3.4. HIV/AIDS
14.3.5. Human Papillomavirus (HPV)
14.3.6. Genital Herpes
14.3.7. Others STDs
14.4. Market Value Forecast By End-user, 2020-2034
14.4.1. Hospitals & Clinics
14.4.2. Diagnostic Laboratories
14.4.3. Others (Research Institutes, Homecare Settings etc.)
14.5. Market Value Forecast By Country, 2020-2034
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type of Diagnostic Test
14.6.2. By Disease Type
14.6.3. By End-user
14.6.4. By Country
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2023)
15.3. Company Profiles
15.3.1. F. Hoffmann-La Roche Ltd
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Thermo Fisher Scientific Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Hologic Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Creative Diagnostics
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Abbott Laboratories
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Quest Diagnostics
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. BD
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. QIAGEN
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Cepheid
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.10. bioMérieux
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview